Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Lung Therapeutics logo — Pioneering safer pathways in lung disease treatment with pha...

Lung Therapeutics

Pioneering safer pathways in lung disease treatment with pharmaceutical solutions.

Founded 2013 11-50 employees Series C Total: $53.91M Biotechnology, Health Care +1

General Information

Company Name Lung Therapeutics
Founded Year 2013
Employees 11-50
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Series C
Social

BounceWatch is an independent company data service, not affiliated with Lung Therapeutics. To contact Lung Therapeutics, visit lungtx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Lung Therapeutics compare?

A PDF of Lung Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Lung Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Lung Therapeutics

Lung Therapeutics, founded in 2013, is a biotechnology and healthcare startup that is pioneering safer pathways in lung disease treatment with pharmaceutical solutions. The company's focus is on niche, orphan drug indications for lung injury and diseases, particularly fibrosis. Their primary current project involves addressing loculated pleural effusion, a severe complication of pneumonia where fluid accumulates in the chest cavity surrounding the lungs, and fibrinous scar tissue obstructs fluid drainage. Their initial product, LTI-01 (single chain urokinase plasminogen activator, or scuPA), is under study for the safe removal of fibrinous scar tissue in patients with loculated pleural effusion. This pharmaceutical intervention aims to significantly improve the clinical pathway for these patients, allowing for simple draining of pleural fluid without the need for surgery. In June 2019, the company received a $36.00M Series C investment from Bios Partners. The long-term focus of Lung Therapeutics' efforts will be on enhancing clinical pathways for Acute Lung Injury, Idiopathic Pulmonary Fibrosis, and other related disease conditions. Lung Therapeutics is a promising player in the biotechnology and healthcare industries, with a strong focus on addressing critical unmet medical needs within the field of lung diseases. The recent investment from Bios Partners underscores investor confidence in the potential of the company's pharmaceutical solutions for improving the treatment of lung-related conditions.

Business keywords: Pharmaceutical Solutions, Lung Disease Treatment, Orphan Drug Indications, Pulmonary Fibrosis, Loculated Pleural Effusion, Fibrinous Scar Tissue, Clinical Pathways, Acute Lung Injury, Idiopathic Pulmonary Fibrosis, Drug Development, Medical Innovation

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Series C $36.00M 1
Bios Partners
Bios Partners
04 Jun 2019
Series B $14.30M 2
Bios Partners UT Horizon Fund
Bios Partners, UT Horizon Fund
06 Jun 2017
Venture Round $1.05M -
07 Mar 2016
Series A $2.57M 1
UT Horizon Fund
UT Horizon Fund
30 Sep 2015
Non Equity Assistance Undisclosed 1
Texas Venture Labs
20 Dec 2013
Convertible Note Undisclosed 1
UT Horizon Fund
UT Horizon Fund
01 Jul 2013

Lung Therapeutics Alternatives & Competitors

View All Alternatives
Lung Therapeutics vs
Aileron Therapeutics
Aileron Therapeutics United States

Developing novel medicines to provide better treatment options for patients with life-threatening pu...

Post-IPO Equity
17 employees
Biopharma, Biotechnology
Lung Therapeutics vs
NeRRe Therapeutics Ltd
NeRRe Therapeutics Ltd United Kingdom

Developing a breakthrough treatment for the disabling chronic cough associated with idiopathic pulmo...

Series B
9 employees
Biotechnology, Health Care
Lung Therapeutics vs
ImmuneWorks
ImmuneWorks

Pioneering safe and effective treatments for autoimmune lung diseases through groundbreaking discove...

Venture round
Biotechnology, Health Care
View all alternatives

FAQ About Lung Therapeutics

Pioneering safer pathways in lung disease treatment with pharmaceutical solutions.
Lung Therapeutics was founded in 2013.
Lung Therapeutics operates in Biotechnology, Health Care and Health and Wellness. Its work centres on Pharmaceutical Solutions, Lung Disease Treatment, Orphan Drug Indications and Pulmonary Fibrosis.
Lung Therapeutics has approximately 11-50 employees.
Lung Therapeutics has completed 6 funding rounds, raising a total of $53.91M. The latest funding stage is Series C.
Top alternatives and competitors to Lung Therapeutics include Aileron Therapeutics, NeRRe Therapeutics Ltd, ImmuneWorks. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Lung Therapeutics and Aileron Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Lung Therapeutics, https://bouncewatch.com/company/lung-therapeutics, updated 10 November 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout